Episode 184: PREMIUM - Two more blood pressure/chlolesterol changing drugs that are a flop

In episode 184, James and Mike don their PREMIUM critical appraisal hats yet again to report the results of important recent studies that examine the impact two “new” drugs, aliskiren and dalcetrapib, have on clinically important outcomes.

 

The full content of this Podcast, including the audio file, is available to Premium Members only. Click to find out the benefits of having a Premium Membership.

Why Get A Premium Membership ?